A modern generation of drug-eluting stents. Focusing on a sirolimus-eluting stent Calypso

Abstract

<p>The review deals with the evolution of interventional coronary procedures and development of the state-of-art coronary stent market. Emphasis in the review is placed on comprehensive analysis of technical characteristics of the world’s most popular coronary stents versus a Russian bioresorbable sirolimus-eluting stent “Calipso”.</p><p>Received 13 January 2017. Accepted 17 March 2017.</p><p><strong>Conflict of interest:</strong> Kudryashov A.N., Trebushat D.V. are “Angioline” Company employees, the producer of “Kalipso” coronary stent. Kretov E.I. served as executive editor of “Endovascular surgery” section. All other authors declare no conflict of interest.</p>